

Determination of Fatty Acid Ethyl Esters in Dried Blood Spots by LC-MS/MS as Markers for Ethanol Intake – Application in a Drinking Study

Authors:

Marc Luginbühl¹, Alexandra Schröck¹, Stefan König¹, Stefan Schürch², Wolfgang Weinmann¹

Affiliations:

¹Institute of Forensic Medicine, University of Bern, Switzerland

²Department of Chemistry and Biochemistry, University of Bern, Switzerland

Addresses:

¹Institute of Forensic Medicine, University of Bern
Bühlstrasse 20
3012 Bern
Switzerland

²Department of Chemistry and Biochemistry, University of Bern
Freiestrasse 3
3012 Bern
Switzerland

Corresponding author:

Marc Luginbühl
Institute of Forensic Medicine, University of Bern
Bühlstrasse 20
3012 Bern
Switzerland
Email: marc.luginbuehl@irm.unibe.ch

Abstract

The forensic utility of fatty acid ethyl esters (FAEEs) in dried blood spots (DBS) as short-term confirmatory markers for ethanol intake was examined. An LC-MS/MS method for the determination of FAEEs in DBS was developed and validated to investigate FAEE formation and elimination in a drinking study, whereby eight subjects ingested 0.66 to 0.84g/kg alcohol to reach blood alcohol concentrations (BAC) of 0.8g/kg. Blood was taken every 1.5-2 hours, BAC was determined and dried blood spots were prepared, with 50 microliters of blood, for the determination of FAEEs. Lower limits of quantitation (LLOQ) were between 15 ng/mL and 37ng/mL for the four major FAEEs. Validation data are presented in detail. In the drinking study, ethyl palmitate and ethyl oleate proved to be the two most suitable markers for FAEE determination. Maximum FAEE concentrations were reached in samples taken 2 or 4 hours after the start of drinking. The following mean peak concentrations (\bar{c}_{\max}) were reached: ethyl myristate 14 ± 4 ng/mL, ethyl palmitate 144 ± 35 ng/mL, ethyl oleate 125 ± 55 ng/mL, ethyl stearate 71 ± 21 ng/mL, total FAEEs 344 ± 91 ng/mL. Detectability of FAEEs was found to be on the same timescale as BAC. In liquid blood samples containing ethanol, FAEE concentrations increase post-sampling. –This study shows, that the use of DBS fixation prevents additional FAEE formation in blood samples containing ethanol. Positive FAEE results obtained by DBS analysis can be used as evidence for the presence of ethanol in the original blood sample.

Keywords. - FAEE, Fatty Acid Ethyl Ester, Alcohol Marker, Abstinence Monitoring, Whole Blood, LC-MS/MS, Dried Blood Spots

Introduction

Alcohol abuse and its medical and social effects pose a major challenge in today's society. In order to prove alcohol abstinence, various secondary alcohol markers are currently analyzed in blood, urine, and hair, such as ethyl glucuronide (EtG), ethylsulfate (EtS) and phosphatidylethanol (PEth) [1]. Fatty acid ethyl esters are non-oxidative short-time metabolites that are generally not included in routine analysis [2]. FAEE metabolites are detectable in blood when ethanol is present and up to 24 hours after alcohol intake [3]. FAEE formation is mainly catalyzed by FAEE synthases and acyl-CoA: ethanol O-acyltransferases (AEAT), which form fatty acid ethyl esters by esterification of ethanol with endogenous fatty acids or fatty acyl-CoA. Based on their chemical structure, FAEEs have a tendency to bind to albumin and lipoproteins, both of which serve as transporters between different lipid compartments. Although at least 15 different FAEEs have been identified in the human body, four FAEEs in particular are used as ethanol consumption-related markers: ethyl myristate (14:0), ethyl palmitate (16:0), ethyl stearate (18:0) and ethyl oleate (18:1). Until recently, the detection of FAEEs was predominantly based on GC/MS and SPME-GC/MS methods for hair samples and meconium, whereby the total FAEE concentration was summed up [1, 2]. Analysis of FAEEs by using LC-MS/MS was first published in 2014, whereby *in utero* ethanol exposure in meconium was identified [4]. This paper provides detailed profiles of the four particular FAEE during a drinking study and can be compared to the work of Doyle et al. [3], where the total FAEE concentration in relation to the blood alcohol concentration was investigated. However, our DBS method prevents FAEE formation post-sampling and exhausts the potential of present-day instrumentation by using low sample volume. LC-MS/MS was the method of choice, as SPME-GC/MS and GC/MS could not provide the required sensitivity, when only using microliter amounts of blood. Furthermore, endogenous fatty acid concentrations were detected and quantified by using linear regression.

Materials and Methods

Reagents

Ethyl myristate, ethyl palmitate, and ethyl stearate were purchased from Lipomed (Arlesheim, Switzerland). Ethyl oleate (98%) was obtained from Sigma Aldrich (Buchs, Switzerland). Pentadeuterated internal standards, D₅-ethyl myristate, D₅-ethyl palmitate, D₅-ethyl stearate and D₅-ethyl oleate were ordered from Toronto Research Chemicals (Toronto, Canada). Acetonitrile (MeCN) HPLC for gradient analysis was purchased from Acros Organics (New Jersey, USA) and water was produced in-house with a Milli-Q water system from Millipore (Billerica, USA). Dried dimethyl sulfoxide (DMSO) (max. 0.05% H₂O, purity ≥99.5%) and EMSURE® n-heptane for analysis (>99%) were obtained from Merck (Darmstadt, Germany). Pure ethanol HPLC grade was obtained from Merck (Darmstadt, Germany). Formic acid puriss. p.a. for HPLC (50% in water) and Whatmann® #903 CF12® protein saver paper were ordered from Sigma Aldrich (Buchs, Switzerland). Anticoagulant citrate phosphate dextrose (CPD) treated blank whole blood for the calibration and the quality control samples was delivered from the local blood collection center (Bern, Switzerland). The anticoagulant lithium heparin was used to obtain whole blood samples during the drinking study.

Study Design

Eight volunteers (6 men, 2 women, aged 19 to 26 years), who had been abstinent for at least two weeks, ingested a single dose of alcohol (66-proof/37.5% vodka mixed with a soft drink), which led to an approximate BAC of 0.8 g/kg. The alcohol doses (125-210mL) were calculated for each test person by the Widmark formula with individually adjusted reduction factors based on the weight and size of the individual [5]. Blank blood samples were obtained from all subjects prior to the experiment. 100 minutes after the start of drinking, the first blood sample was taken. Three more samples were taken during the next 5 hours. All blood samples were directly spotted on protein saver filter paper to create DBS.

Sample Preparation

FAEEs were analyzed in DBS generated from lithium-heparinized blood by spotting 50 μL of blood onto a Whatmann® #903 CF12® protein saver paper. Before extraction, the DBS were dried at room temperature for at least 3 hours.

Determination of BAC

BAC was determined in lithium-heparinized blood in house by a validated headspace gas chromatography method with flame ionization detection (HS-GC-FID). According to Swiss forensic guidelines, the samples were analyzed with two GC-FID systems with two measurements each, analogously to BAC determination in serum [6].

Determination of FAEEs

For analyzing ethyl myristate (C14), ethyl palmitate (C16), ethyl oleate (C18:1), and ethyl stearate (C18), a DBS generated from 50 μL of blood was cut out and 20 μL of internal standard (D₅-ethyl myristate (C14) 75 ng/mL, D₅-ethyl palmitate (C16) 62.5 ng/mL, D₅-ethyl oleate (C18:1) 125 ng/mL, and D₅-ethyl stearate (C18) 62.5 ng/mL), 500 μL of DMSO and 1000 μL n-heptane were pipetted into a micro tube and mixed for 20 minutes at 1500 rpm on a VIBRAX VXR basic from IKA (Staufen, Germany). Afterwards, the samples were centrifuged for 10 min at 16'000 g. The samples were placed in the freezer at about -18°C for 30 minutes to congeal the DMSO and simplify the transfer of the supernatant to a 1.5 mL snap/crimp champagne glass vial. The organic phase was evaporated until dry at 60°C under vacuum (approximately 180 mbar) with a CentriVap concentrator from LABCONCO® (Biolabo Scientific Instruments, Switzerland). The residue was dissolved in 300 μL acetonitrile. An aliquot of 5 μL was injected into the LC-MS/MS system. A blank (whole blood from an abstinent person without internal standard) and a zero sample (whole blood from an abstinent person with internal standard) were always included.

FAEE *in vitro* production

5 mL of fresh, lithium heparinized blood was spiked immediately after sampling with 6.3 μL , 12.6 μL , and 18.9 μL ethanol to obtain a BAC of 1, 2, and 3 g/kg ($\pm 0.05\text{g/kg}$), respectively. After spiking, the blood was incubated at 37°C and a 50 μL DBS was generated every ten minutes during the first hour to monitor FAEE production. The blank sample at $t = 0$ did not contain any alcohol.

Method validation

Method validation for the determination of FAEEs in DBS was performed according to FDA guidelines with a standard addition correction for endogenous levels [7]. Selectivity, linearity, limit of quantification, imprecision (expressed as the relative standard deviation (RSD%)), accuracy (expressed as the mean relative error (RE%)), and carry-over were investigated. Selectivity was determined by testing six blank samples of blood from alcohol abstinent people (abstinence period of more than 2 weeks) and from swine for interferences of endogenous matrix components or metabolites, which could disturb the signals of FAEEs or internal standards. Additionally, the feasibility of a standard addition-based method was investigated, by using blank blood from an abstinent subject. CPD treated blood from an abstinent person was used for calibration and quality control samples. Working solutions containing all four FAEEs (0.2, 0.4, 1, 2, 5, 10, 15, 20, and 40 $\mu\text{g/mL}$) for the calibration samples were prepared in acetonitrile and 10 μL of each were spiked in 190 μL of blank blood. The calibrators had the following concentrations: 10, 20, 50, 100, 250, 500, 750, 1000, and 2000 ng/mL. Nine-point calibration curves of FAEEs were recorded twice on three different days. Precision and accuracy were determined by preparing blood samples (quality control samples, QC) spiked at different FAEE concentration levels: 10, 20, 30, 50, 150, 600, and 1500 ng/mL. Carry-over was measured by injecting the highest calibrator (2000 ng/mL) three times, followed by a blank blood sample in duplicate to test if substances from the previous injection were carried over to the next measurement. Matrix effects, recovery, and extraction efficiency were analyzed by post extraction addition. Corrections for

endogenous FAEE concentrations were made at the end of the measurement by correcting for the absolute value of the x-axis intercept from the individual calibration curve.

Instrumentation

The LC-MS/MS system was composed of an UltiMate[®] 3000 UHPLC+ focused system with an UltiMate[®] 3000 RS autosampler and a heated column compartment from Dionex (Olten, Switzerland) with a QTrap 5500 mass spectrometer from Sciex (Toronto, Canada), controlled by Analyst 1.6.2 software. Chromatographic separation was performed with a core-shell Kinetex 2.6 μ , C8, 100 \AA , 50 \times 2.1 mm column from Phenomenex (Torrance, USA), heated at 40°C, with a flow rate of 0.5 mL/min. Mobile phase A consisted of water with 0.1% formic acid, mobile phase B consisted of acetonitrile with 0.1% formic acid. The FAEEs, depicted in table 1, were analyzed with the following 8 min gradient: 0 to 0.5 min, 20% B; 0.5 to 1.5 min, 20 to 70% B linear; 1.5 to 5 min, 70 to 97.5% B linear; 5 to 6 min, 97.5% B; 6 to 6.1 min 97.5 to 20% B linear, 6.1 to 8 min, 20% B. The mass spectrometer was operated in electrospray positive MRM mode with an ion spray voltage of 5000V and a source temperature of 650°C, collision gas at medium 40, curtain gas: 40, gas1: 40, gas 2: 40.

Table 1.- MS/MS parameters and retention time for FAEEs quantitation from DBS.

Analyte	Q1 [m/z]	Q3 [m/z]	Time [msec]	DP [volts]	CE [volts]	CXP [volts]	RT [min]
Ethyl Myristate	257.2	229.2	30	85	15	20	3.27
	257.2	103	30	85	22	12	
	257.2	247.2	30	85	10	22	
Ethyl Myristate-d5	262.2	230.3	20	81	15	16	3.26
Ethyl Palmitate	285.1	257.3	30	41	15	22	3.74
	285.1	71.1	30	41	21	34	
Ethyl Palmitate-d5	290.3	258.4	20	86	17	12	3.72
Ethyl Oleate	311.2	265.3	30	100	15	24	3.86
	311.2	247.2	30	100	17	20	
Ethyl Oleate-d5	316.3	265.4	20	86	15	22	3.84
Ethyl Stearate	313.1	285.3	30	46	17	22	4.21
	313.1	71.1	30	36	25	10	
Ethyl Stearate-d5	318.3	286.2	20	56	17	22	4.20

Results and Discussion

Method Validation

Regarding selectivity, the measured samples had to be corrected for endogenous FAEE concentrations to obtain valid results, as there was no blood available which did not contain any FAEEs. Extracted ion chromatograms for a blank blood specimen and a calibrator (K3, 50ng/mL) are shown in figure 1. The endogenous FAEE levels of 14 abstinent individuals proved to be close to each other (total FAEEs 40-67 ng/mL), swine blood contained larger amounts of FAEEs (total FAEEs 190 ng/mL) and could therefore not be used as blank blood. To analyze the linearity of the developed method, a linear calibration model with weighting $1/x^2$ was used with spiked concentrations in the range of 10-2000 ng/mL. Extracted ion chromatograms for MRM1, MRM2 and internal standards are shown in figure 2. All calibration curve correlation coefficients (R^2) from least square regression were >0.994 . With respect to the mean endogenous concentration from the validation measurements, lowest calibrator (10 ng/mL) for ethyl myristate, ethyl palmitate, and ethyl oleate, and 20 ng/mL for ethyl stearate fulfilled the validation criteria. The following LLOQ were established after the correction for endogenous FAEE concentrations by linear regression: ethyl myristate 15 ng/mL, ethyl palmitate 26 ng/mL, ethyl oleate 14 ng/mL, ethyl stearate 37 ng/mL. The limit of detection (LOD) was not established, as the samples are corrected for endogenous levels by the standard addition procedure. Imprecision and accuracy were in acceptable ranges. All QC samples had measured concentrations within $\pm 15\%$ of target, in accordance with FDA guidelines [7]. Mean intra assay accuracy was 89.1-108.9% and mean inter assay accuracy 94.1-110.7% of target. Intra assay imprecision was 1.3-14.6% and inter assay imprecision 0.6-14.3% (Supplementary Data, Table S1).




Figure 1.- Typical chromatogram of blank whole blood (a) and whole blood spiked with K3 (50ng/mL) (b). MRM1: ethyl myristate (blue), ethyl palmitate (red), ethyl oleate (green), and ethyl stearate (grey).




Figure 2.- Detailed chromatogram for ethyl myristate (a), ethyl palmitate (b), ethyl oleate (c), and ethyl stearate (d) at concentration K3 with MRM1 (blue), MRM2 (red) and internal standard (green)

No evidence for carry-over was found. All FAEEs demonstrated adequate extraction efficiency of 40-69%, recovery was 40-75%, FAEE matrix effects were 93-113%, depicted in Table 2. Extracted samples were stable up to 72 hours in the autosampler, after 3 freeze thaw cycles at about -18°C, and after storage for 7 days at about -18°C. However, after extraordinarily long storage (7 days) at room temperature, quality control samples (prepared as DBS) showed a large variation of measured concentrations, compared to samples prepared and analyzed on day 0. QC showed increases (up to 41%) and decreases (up to -52%) of the FAEE concentrations. This finding implies that the long-term stability of analytes has to be taken into account. DBS samples collected during the drinking study were within ±13% of immediate measurement when extracted after one week of storage (samples & calibrators stored at room temperature). Due to the observed instability, DBS were extracted within 24 hours after their generation. Furthermore, samples which were analyzed and compared together (quality control, calibration, drinking study) were always prepared and extracted simultaneously.

Table 2.- Extraction efficiency, recovery and matrix effect for FAEEs in DBS

^a low QC concentration was 50 ng/mL for all FAEEs.

^b high QC concentration was 600 ng/mL for all FAEEs.

Analyte	extraction efficiency (n=2)		recovery (n=2)		matrix effect (n=2)	
	low ^a	high ^b	low	high	low	high
ethyl myristate	40%	45%	40%	42%	99%	93%
ethyl palmitate	55%	60%	51%	63%	93%	105%
ethyl oleate	59%	61%	55%	62%	96%	101%
ethyl stearate	59%	69%	67%	75%	113%	110%

***In vitro* FAEE production**

After the addition of ethanol, FAEE levels above the LLOQ were obtained for all four FAEEs. The biggest alcohol concentration-related increase in FAEE concentration was observed for ethyl palmitate and ethyl oleate. After thirty minutes, FAEE concentrations above the LLOQ were reached for all concentrations of alcohol. Ethyl stearate concentrations above the LLOQ were found for samples containing at least 2 g/kg of BAC and after 210 minutes only. Ethyl myristate showed concentrations above the LLOQ for all three alcohol concentrations after 50 minutes,

whereby no distinction was possible concerning the alcohol concentration spiked to the sample. Detailed time courses for the increase in *in vitro* FAEE concentrations are shown in figure 3. This *in vitro* experiment clearly demonstrated the necessity of immediate DBS fixation to measure FAEE concentrations reliably.




Fig 3.- Time courses for *in vitro* fatty acid ethyl ester (FAEE) concentrations for the four investigated substances over a time period of 210 minutes after spiking the blood for BAC of 1, 2 and 3 g/kg.

Drinking study results

The group of participating volunteers was very homogenous in age and body mass index (BMI) with a mean age of 23.5 ± 2.4 years (range: 19-26 years) and a BMI of 21.3 ± 2.5 kg/m² (range: 17.7-25.1 kg/m²). All blood samples collected prior to drinking were tested negative for ethanol and below or close to the LLOQ for all FAEEs. Maximum BACs were reached 1.75 hours after the start of drinking with a mean maximum BAC of 0.76 ± 0.06 g/kg (range: 0.66-0.84 g/kg). After drinking the calculated amounts of vodka, the following mean maximal concentrations were reached: ethyl myristate $\bar{c}_{\max} = 14 \pm 4$ ng/mL, ethyl palmitate $\bar{c}_{\max} = 144 \pm 35$ ng/mL, ethyl oleate $\bar{c}_{\max} = 125 \pm 55$ ng/mL, and ethyl stearate $\bar{c}_{\max} = 71 \pm 21$ ng/mL, total FAEEs $\bar{c}_{\max} = 344 \pm 91$ ng/mL. Figure 4 shows the time courses of each subject. There was a significant overlap between the curves for BAC and FAEE concentration over the time course. The peak of the BAC and FAEE concentrations were found to be very close. Subject 1-7 showed similar FAEE profiles, subject 8 showed a delayed FAEE formation. As shown in the *in vitro* experiments, FAEE formation started immediately after alcohol ingestion and increased to a maximum during the first four hours. After 4 hours the concentration of FAEEs in the blood decreased. FAEE concentrations around the LLOQ were observed after 7 hours, when BAC reached zero. Although the concentrations for all FAEEs in all the subjects' samples increased after the consumption of alcohol, only 5 participants reached ethyl myristate levels above the LLOQ. Ethyl palmitate and ethyl oleate showed the highest increase. In comparison, ethyl stearate, with a relatively high LLOQ of 37 ng/mL, showed concentrations above the LLOQ only for a short time. Detailed time courses for BAC and FAEE concentrations in different subjects are depicted in figure 4. FAEE concentrations above the endogenous level were not detected after 24 or 48 hours.




Fig 4.- Time courses for fatty acid ethyl ester (FAEE) concentrations in DBS and ethanol concentration for subject 1-8 over a period of 7 hours. Ethanol ingestion occurred during the first hour of the time course.

Conclusion

The results of this study indicate that whole blood DBS FAEE analysis may be useful as a short-term confirmation for ethanol ingestion or in the absence of liquid samples (e.g. blood spots in crime scenes). However, matrix samples without blood contamination would need further investigation (as a control sample) and further method validation would be necessary[8]. Especially during PEth analysis [9, 10], where DBS fixation proved to be beneficial to prevent *in vitro* formation, FAEE analysis could serve as a second alcohol marker to monitor recent alcohol consumption. The detectability of FAEE concentrations in blood was found to be very similar to those of ethanol. A terminal half-life, which would allow a detection for up to 24 hours [3] was not found with a target BAC of 0.8 g/kg. Endogenous FAEE concentrations were observed and quantified using standard addition method. Ethyl palmitate and ethyl oleate appeared to be the two most useful FAEE, as concentrations above the LLOQ are easily reached. The application of DBS in FAEE analysis provides a safe and easy method to inhibit *in vitro* FAEE formation. Furthermore extraction is simplified when using DBS, as no time-consuming SPE is needed, compared to analysis in blood serum with GC-MS [3]. The use of a LC-MS/MS method proved to be beneficial compared to preliminary tests with GC-MS [3] and SPME-GC/MS [11] methods, which could not provide the same sensitivity. In addition, the run-time of a LC-MS/MS measurement (eight minutes) is about four times faster than a SPME-GC/MS method

(extraction of 20-30 minutes and analysis of 10 minutes). [12] Further studies are necessary to investigate the relationship between blood fatty acid content and the formation of FAEEs.

Acknowledgements

We would like to thank Sidonia Guggisberg, Anita Iannone, Anja Kaiser, Severine Krönert, Nadja Utiger and Thomas Wüthrich of the Forensic Toxicology and Chemistry Laboratory of the Institute of Forensic Medicine Bern for the determination of blood alcohol concentrations.

Conflict of Interest

The authors declare that they have no conflict of interest

Funding

The drinking study and one of the authors (A. Sc.) was supported by the Swiss Foundation of Alcohol Research (Grant 254/2014: Studies on phosphatidylethanol (PEth) – a promising biomarker for the detection of harmful ethanol consumption – and its possible use for abstinence monitoring).

Compliance with Ethical Standards

The drinking study has been approved by the Cantonal Ethics Commission Bern (064/13) on March 03, 2014.

1. Schrock, A., et al., *Progress in monitoring alcohol consumption and alcohol abuse by phosphatidylethanol*. *Bioanalysis*, 2014. **6**(17): p. 2285-94.
2. Best C. A. and Laposata M., *Fatty acid ethyl esters: toxic non-oxidative metabolites of ethanol and markers of ethanol intake*. *Front Biosci*, 2003. **1**(8): p. e202-17.
3. Doyle K. M., et al., *Fatty acid ethyl esters in the blood as markers for ethanol intake*. *JAMA*, 1996. **276**(14): p. 1152-1156.
4. Himes S. K., et al., *Validation of a novel method to identify in utero ethanol exposure: simultaneous meconium extraction of fatty acid ethyl esters, ethyl glucuronide, and ethyl sulfate followed by LC-MS/MS quantification*. *Anal Bioanal Chem*, 2014. **406**(7): p. 1945-55.
5. Ulrich L., Cramer Y., and Zink P., *Die Berücksichtigung individueller Parameter bei der Errechnung des Blutalkoholgehaltes aus der Trinkmenge*. *Blutalkohol*, 1987. **24**: p. 192-198.
6. Aderjan R., e.a., *Richtlinien zur Bestimmung der Blutalkoholkonzentration (BAK) für forensische Zwecke*. 2011. **48**: p. 137-143.
7. *U.S. Department of Health and Human Services FDA. Rockville U (2001) Guidance for Industry: Bioanalytical Method Validation*. . 11.11.2015].
8. Winkler, M., et al., *Detection of ethyl glucuronide in blood spotted on different surfaces*. *Forensic Sci Int*, 2011. **210**(1-3): p. 243-246.
9. Bakhireva L. N., et al., *The feasibility and cost of neonatal screening for prenatal alcohol exposure by measuring phosphatidylethanol in dried blood spots*. *Alcohol Clin Exp Res*, 2013. **37**(6): p. 1008-15.
10. Faller A., et al., *LC-MS/MS analysis of phosphatidylethanol in dried blood spots versus conventional blood specimens*. *Anal Bioanal Chem*, 2011. **401**(4): p. 1163-6.
11. Auwärter V., et al., *Fatty acid ethyl esters in hair as markers of alcohol consumption. Segmental hair analysis of alcoholics, social drinkers, and teetotalers*. *Clin Chem*, 2001. **47**(12): p. 2114-23.
12. Auwärter, V., *Fettsäureethylester als Marker exzessiven Alkoholkonsums - Analytische Bestimmung im Haar und in Hautoberflächenlipiden mittels Headspace-Festphasenmikroextraktion und Gaschromatographie-Massenspektrometrie*, in *Mathematisch-Naturwissenschaftlichen Fakultät I2006, Humboldt-Universität zu Berlin*. p. 181.

Supplementary Data

Table 3.- Mean accuracy and imprecision results for FAEEs in DBS at 7 quality control concentrations.

Analyte	concentration (ng/mL)	intra assay accuracy (% , n=6)	inter assay accuracy (% , n=3)	intra assay imprecision (% , n=6)	inter assay imprecision (% , n=3)
ethyl myristate	10	99.5	106.6	3.7	11.0
	20	108.9	110.7	2.8	6.0
	30	106.0	107.6	1.3	2.3
	50	100.4	104.8	2.5	3.8
	150	100.7	104.0	3.0	4.9
	600	100.3	104.4	3.6	4.0
	1500	102.7	105.1	3.1	2.6
ethyl palmitate	10	89.1	94.1	4.7	6.2
	20	94.0	104.5	5.2	14.3
	30	101.6	101.5	3.7	5.2
	50	106.8	106.9	6.7	4.4
	150	98.7	97.9	3.8	4.2
	600	98.1	98.2	4.7	4.8
	1500	102.0	100.5	3.2	1.5
ethyl oleate	10	98.5	104.0	8.8	10.0
	20	102.8	101.3	5.4	3.3
	30	108.1	102.8	3.6	4.9
	50	105.0	105.5	6.1	8.5
	150	99.9	99.8	3.3	0.6
	600	98.6	100.8	2.3	12.0
	1500	100.4	100.0	2.5	1.7
ethyl stearate	20	99.6	99.0	13.8	8.3
	30	105.0	99.2	4.3	5.1
	50	104.5	96.8	14.6	7.0
	150	99.4	99.3	4.6	2.3
	600	99.3	97.9	3.3	1.8
	1500	101.8	99.7	5.2	3.0